Nog even een stukje van Anurag Relan uit het belspel met de analisten op 16 maart 2023. Goed om de veelgebruikte 1500 in een ander perspectief te zien
"So, we when we look at the prevalence, and we have good data, for example, in some European countries where if we take France, for instance, where there's already 60 patients identified in a country, that's a population that's about 60 million, so we know the minimum prevalence, again, really without our involvement is, and without a therapy being available, is about one per million. So, we've conservatively estimated about one to two per million in terms of the prevalence, and that's where that 1500 number comes from. Now, as we've been out there talking about the condition, obviously, we're finding more and more patients, including in places like France and across Europe, as well as in the U.S. So, that number we expect to continue to increase. I think a big driver, also of diagnosis, though, is the availability of a potential therapy, a targeted therapy. So, I think, as you know, and hopefully we can have a therapy available for these patients soon. But once such a therapy is available, I think that will drive even further diagnosis. But I think for right now with the estimates that we're providing in terms of the prevalence, but certainly, you know, I don't think it would surprise any of us if the numbers were significantly higher."